About Us:

Eupraxia is a clinical-stage biotechnology company focused on developing locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support an extended duration of effect and delivery of drugs in a hyper-localized fashion, targeting only the tissues that physicians want to treat. We believe the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the DiffuSphere™ technology, versus the peaks and troughs seen with more traditional drug delivery methods. The precision of Eupraxia's DiffuSphere™ technology platform has the potential to augment and transform existing FDA-approved drugs to improve their safety, tolerability, efficacy and duration of effect. The potential uses in therapeutic areas extend beyond pain and inflammatory gastrointestinal disease, where Eupraxia is currently developing advanced treatments, to applications in oncology, infectious disease and other critical disease areas.

Eupraxia's EP-104GI is currently in a Phase 1b/2 trial (RESOLVE) for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. This is a unique treatment approach for EoE. Eupraxia also recently completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. The SPRINGBOARD trial successfully met its primary endpoint and three of the four secondary endpoints. In addition, Eupraxia is developing a pipeline of later and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs. For further details about Eupraxia, please visit the Company's website at: www.eupraxiapharma.com.

We are looking for people who would like to work for a fast-paced, growing company that fosters a creative spirit and integrated teamwork and who are eligible to work in Canada.

Scope

Supports the co-ordination & execution of communication and Investor Relations activities for the company. This role works closely with the cross functional teams and maintains a broad perspective on the business and all key developments within the company, ensuring the effective communication to appropriate constituents. Strong organizational skills and attention to detail, maintaining a high standard of care in terms of compliance for the company.

Reporting to:Director, Corporate Development and Investor Relations

Key responsibilities and duties:

Develop and implement tactics to raise awareness of the Eupraxia story.
Plan and manage logistics for investor events, roadshows, and non-deal conferences.
Track engagement using CRM tools and generate insights.
Follow and summarize industry news and developments with peer groups.
Promote a strong, consistent corporate image and brand across all channels.
Manage the content development and execution of investor-facing materials, including the corporate presentation, website, publications, press releases and messaging documents, ensuring proper internal and external approval, and consistent dissemination.
Oversee the ongoing development of the company’s corporate brand and reputation.
Measure and report on communication effectiveness and press release performance.
Oversee management and content of the corporate website.
Support special projects and perform related duties as required.

Requirements:

Bachelor’s degree in Business, Life Sciences, Communications or related field; post-graduate degree is an asset.
2+ years of experience in investor relations, marketing, or related field.
Experience in a public company, preferably in the biotech, pharmaceutical, or healthcare sectors, is an asset.
Exceptional communication skills—both written and verbal.
Ability to develop clear, compelling PowerPoint presentations.
High attention to detail with excellent organizational and project management abilities.
Strong analytical and problem-solving skills.
Highly proficient with Microsoft Office (Word, Excel, PowerPoint)
Self-starter with a collaborative mindset and ability to work independently.
Demonstrated ability to manage confidential and sensitive information with discretion.
Curiosity of capital markets and biotech investing.

Salary Range: $85,000 to $110,000, depending on education and relevant experience.

While only short-listed candidates will be notified, we thank each applicant for their submission.

Eupraxia Pharmaceuticals Inc. remote jobs

Senior Analyst, Investor Relations and Communications